BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30446660)

  • 1. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
    Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
    Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models.
    Xu P; Yang JC; Ning S; Chen B; Nip C; Wei Q; Liu L; Johnson OT; Gao AC; Gestwicki JE; Evans CP; Liu C
    Pharmacol Res; 2023 Mar; 189():106692. PubMed ID: 36773708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
    Liu C; Armstrong C; Zhu Y; Lou W; Gao AC
    Oncotarget; 2016 May; 7(22):32210-20. PubMed ID: 27049719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heat shock protein 70 inhibitors suppress androgen receptor expression in LNCaP95 prostate cancer cells.
    Kita K; Shiota M; Tanaka M; Otsuka A; Matsumoto M; Kato M; Tamada S; Iwao H; Miura K; Nakatani T; Tomita S
    Cancer Sci; 2017 Sep; 108(9):1820-1827. PubMed ID: 28691182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Liu C; Armstrong CM; Ning S; Yang JC; Lou W; Lombard AP; Zhao J; Wu CY; Yu A; Evans CP; Tepper CG; Li PK; Gao AC
    Oncogene; 2021 Sep; 40(35):5379-5392. PubMed ID: 34272475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
    Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
    Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
    [No Abstract]   [Full Text] [Related]  

  • 7. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C; Schnoeller TJ; Luedeke M; Steinestel K; Boegemann M; Schrader AJ; Steinestel J
    Eur Urol; 2017 Jan; 71(1):1-3. PubMed ID: 27471164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
    Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
    Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
    Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
    Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
    Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.
    Liu Y; Yu C; Shao Z; Xia X; Hu T; Kong W; He X; Sun W; Deng Y; Liao Y; Huang H
    Cell Death Dis; 2021 Sep; 12(10):857. PubMed ID: 34548474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
    Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
    Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-v7 protein expression is regulated by protein kinase and phosphatase.
    Li Y; Xie N; Gleave ME; Rennie PS; Dong X
    Oncotarget; 2015 Oct; 6(32):33743-54. PubMed ID: 26378044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
    Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
    Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
    Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
    Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells.
    Dong J; Wu Z; Wang D; Pascal LE; Nelson JB; Wipf P; Wang Z
    Mol Cancer Ther; 2019 Jan; 18(1):39-50. PubMed ID: 30297360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.